On one hand, CRISPR/Cas9 can be used to target oncogenic gene destruction, such as CRISPR-LNP (lipid nanoparticle) delivery system can deliver Cas9 mRNA to glioblastoma cells to specifically knock down oncogenic genes (e.g., EGFRvIII), which significantly extends the survival period of mice; on the other hand, in the personalized immunotherapy, CRISPR editing of the PD-1 gene of T cells can enhance the effect of CAR-T cells on tumor cells. This evidence concerns the gene SNCA and neoplasm.